REPLY: Mineralocorticoid Receptor Antagonism in Acute Myocardial Infarction Who Benefits?

被引：0
|
作者：
Beygui, Farzin [1 ]
Montalescot, Gilles [1 ]
机构：
[1] Pitie Salpetriere Univ Hosp, Inst Cardiol, 47 Blvd Hop, F-75013 Paris, France
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2016年 / 68卷 / 20期
关键词：
EPLERENONE; BLOCKADE;
D O I：
10.1016/j.jacc.2016.07.783
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2241 / 2242
页数：3
相关论文
共 50 条
  • [21] Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?
    Docherty, Kieran F.
    Jhund, Pardeep S.
    HEART, 2018, 104 (22) : 1812 - 1813
  • [22] Mineralocorticoid receptor antagonist use in eligible patients following acute myocardial infarction: Real world data from the Acute Coronary Syndrome Israeli Surveys: 2004-2010
    Koifman, Edward
    Kopel, Eran
    Maor, Elad
    Fefer, Paul
    Matezky, Shlomi
    Tofler, Goeffrey
    Hamdan, Ashraf
    Grossman, Ehud
    Goldenberg, Ilan
    Klempfner, Robert
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (04) : 3971 - 3976
  • [23] Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
    Bedrouni, Wassim
    Sharma, Abhinav
    Pitt, Bertram
    Lam, Carolyn S. P.
    Ni, Jiayi
    Ferreira, Joao Pedro
    McMurray, John
    Giannetti, Nadia
    Girerd, Nicolas
    Rossignol, Patrick
    Solomon, Scott D.
    Claggett, Brian
    Pocock, Stuart
    Huynh, Thao
    Zannad, Faiez
    CIRCULATION-HEART FAILURE, 2022, 15 (10)
  • [24] Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation
    Wei, Yongzhong
    Whaley-Connell, Adam T.
    Habibi, Javad
    Rehmer, Jenna
    Rehmer, Nathan
    Patel, Kamlesh
    Hayden, Melvin
    DeMarco, Vincent
    Ferrario, Carlos M.
    Ibdah, Jamal A.
    Sowers, James R.
    HYPERTENSION, 2009, 53 (02) : 158 - U101
  • [25] Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
    Bramlage, Peter
    Swift, Stephanie L.
    Thoenes, Martin
    Minguet, Joan
    Ferrero, Carmen
    Schmieder, Roland E.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (01) : 28 - 37
  • [26] Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
    Bonnard, Benjamin
    Pieronne-Deperrois, Marie
    Djerada, Zoubir
    Elmoghrabi, Soumaya
    Kolkhof, Peter
    Ouvrard-Pascaud, Antoine
    Mulder, Paul
    Jaisser, Frederic
    Messaoudi, Smail
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2018, 121 : 124 - 133
  • [27] MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY A Pilot Study
    Bousquet, Elodie
    Beydoun, Talal
    Zhao, Min
    Hassan, Leila
    Offret, Olivier
    Behar-Cohen, Francine
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (10): : 2096 - 2102
  • [28] Interactions of Enhanced Urocortin 2 and Mineralocorticoid Receptor Antagonism in Experimental Heart Failure
    Rademaker, Miriam T.
    Charles, Christopher J.
    Nicholls, M. Gary
    Richards, A. Mark
    CIRCULATION-HEART FAILURE, 2013, 6 (04) : 825 - 832
  • [29] Evaluating the efficacy of mineralocorticoid receptor antagonism in patients with STEMI without heart failure
    Scirica, Benjamin M.
    EUROPEAN HEART JOURNAL, 2014, 35 (34) : 2276 - 2278
  • [30] Sex-Specific Impact of Aldosterone Receptor Antagonism on Ventricular Remodeling and Gene Expression after Myocardial Infarction
    Kanashiro-Takeuchi, Rosemeire M.
    Heidecker, Bettina
    Lamirault, Guillaume
    Dharamsi, Jennifer W.
    Hare, Joshua M.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2009, 2 (02): : 134 - 142
12345